AstraZeneca PLC (AZN)
| Market Cap | 267.01B +18.5% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 25.56 |
| Forward PE | 15.90 |
| Dividend | $3.23 (1.87%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 4,739,125 |
| Open | 170.70 |
| Previous Close | 169.64 |
| Day's Range | 170.67 - 174.44 |
| 52-Week Range | 141.77 - 212.71 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 213.59 (+23.84%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $213.59, which is an increase of 23.84% from the latest price.
News
AstraZeneca shares soar amid strong demand for cancer treatments
Revenues for the first half rose 6% to £23bn while profits rose 2% to £5bn. Chief exec Pascal Soriot, pictured, pointed to booming sales of specific canc
AstraZeneca (AZN) Reports Strong Q2 Earnings, Reaffirms $80 Billion Revenue Goal
AstraZeneca (AZN) Reports Strong Q2 Earnings, Reaffirms $80 Billion Revenue Goal
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
AstraZeneca (AZN) Reports Strong Q2 Earnings and Raises Dividend
AstraZeneca (AZN) Reports Strong Q2 Earnings and Raises Dividend
AstraZeneca's Sone-Ve (AZN) Shows Promising Results in Late-Stage Gastric Cancer Trial
AstraZeneca's Sone-Ve (AZN) Shows Promising Results in Late-Stage Gastric Cancer Trial
AstraZeneca boss says AI won't replace many jobs at his firm... but will make workers 'smarter and faster'
Pascal Soriot, the chief executive of one of Britain's biggest companies, said that he does not expect a 'big reduction' in jobs at his group due to AI.
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Omeros (OMER) after AstraZeneca (AZN) disclosed that the Phase 3 study of ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopat...
Omeros up 11% to $10.89 after AstraZeneca study failure
10:11 EDT Omeros (OMER) up 11% to $10.89 after AstraZeneca (AZN) study failure
Astrazeneca Q2 Earnings Call Highlights
Astrazeneca NYSE: AZN reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per sha...
AstraZeneca drug prices evolving in response to Trump policy, executive says
AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a s...
AstraZeneca boss urges western drugmakers to move at ‘Chinese speed'
Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot
AstraZeneca (AZN) Increases Interim Dividend to $1.06 Per Share
AstraZeneca (AZN) Increases Interim Dividend to $1.06 Per Share
AstraZeneca (AZN) Aims for $80 Billion Revenue by 2030
AstraZeneca (AZN) Aims for $80 Billion Revenue by 2030
AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint
Results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2...
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales
Strong cancer drug sales lifted Anglo-Swedish pharmaceutical giant AstraZeneca’s second-quarter earnings above expectations, helping the company maintain its 2026 outlook.
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint
AstraZeneca (AZN) reports high-level results from the ALXN1210-TMA-313 Phase 3 clinical trial showed that Ultomiris did not achieve statistical significance for the primary endpoint of event-free surv...
AstraZeneca reports Sone-Ve improved survival in gastric cancers
AstraZeneca (AZN) reports “positive” high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin, or Sone-Ve, demonstrated a statistically significant and high...
AstraZeneca Earnings Call Transcript: Q2 2026
Revised summary: Strong H1 2026 with 6% revenue and 11% core EPS growth, driven by innovative medicines and robust pipeline. Oncology and rare disease saw double-digit growth; respiratory and immunology offset generic losses. Confidence in reaching $80B revenue by 2030 remains high, backed by a diversified late-stage pipeline and ongoing investment.
AstraZeneca Quarterly report: Q2 2026
AstraZeneca has published its Q2 2026 quarterly earnings report on July 27, 2026.
AstraZeneca Slides: Q2 2026
AstraZeneca has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 27, 2026.
AstraZeneca reaffirms FY26 revenue, core EPS guidance
Total Revenue is expected to increase by a mid-to-high single-digit percentage; Core EPS is expected to increase by a low double-digit percentage. The Core Tax rate is expected to be…
AstraZeneca ‘on track’ to deliver ambition of $80B in revenue in 2030
06:06 EDT AstraZeneca (AZN) ‘on track’ to deliver ambition of $80B in revenue in 2030
AstraZeneca reports Q2 core EPS $2.63, up 18% at CER
Reports Q2 revenue $15.4B, consensus $15.42B. Pascal Soriot, CEO, AstraZeneca (AZN), said: “In the first half we saw strong performance and continued pipeline delivery, including six key positive Phas...
AstraZeneca raises interim dividend to $1.06 per share
06:03 EDT AstraZeneca (AZN) raises interim dividend to $1.06 per share